Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)

NCT04493320 is registered in ClinicalTrials.gov with New York State Psychiatric Institute as lead sponsor.

NCT NCT04493320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04493320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)
Lead sponsor
New York State Psychiatric Institute
Phase
Phase 4
Overall status
Terminated
Start date
February 10, 2021
Completion date
October 27, 2021
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive impairment, depression, gait impairment